MedTrace Logo

Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients

NCT04867161 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-06-30

No results posted yet for this study

Summary

Patients suffering from COVID-19 (Coronavirus Disease 2019) pneumonia are prone to bacterial and mycotic superinfection. According to existing evidence, the prevalence of superinfection is about 8% to 14% (95% CI 5-26%). However, the percentage of patients treated for superinfection is as high as 80%. There can be multiple reasons for this difference.

Conditions

Interventions

DIAGNOSTIC_TEST

Inflammatory markers sampling

Laboratory sampling: Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin) BALF (bronchoalveolar lavage fluid) processing protocol: 1. microbiology: microscopic examination, standard cultivation test 2. biochemistry: albumin, total protein 3. Pathology: cytology 4. PCR: a. Multiplex PCR b. SARS-CoV-2 RNA load

Sponsors & Collaborators

  • Masaryk University

    collaborator OTHER

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Jan Maláska · Brno University Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867161 on ClinicalTrials.gov